Search clinical trials for: local relapse

Total 78428 results

Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months (REVOCAN)

Ovarian Cancer

France
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Hematologic Malignancy | Stem Cell Transplant Complications

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (CT32)

Relapsed or Metastatic Non-small Cell Lung Cancer

China
Wuhan Union Hospital, China
Chengdu USino Technology Biology Co., Ltd

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic Leukemia

China
Molecular Templates, Inc.

Recruiting

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Squamous Cell Carcinoma of Head and Neck | Advanced Solid Tumor | Non-small Cell Lung Cancer

United States
Children's National Research Institute

Recruiting

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

Soft Tissue Sarcoma | Ewing Sarcoma | Bone Metastases | Solid Tumors | Rhabdomyosarcoma | Wilms Tumor | Germ Cell Tumor | Hepatic Tumor | Malignant Epithelial Neoplasm

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Hematological Malignancies

China
Celgene

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, France, Canada
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
Istituto Scientifico Romagnolo per lo Studio e...

Not yet recruiting

Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients With Prostate Cancer. (F-PSMA)

Prostate Cancer | 18F-PSMA

Italy
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Unresectable Hepatocellular Carcinoma

Canada, France, Korea, Republic of, China, Japan, Spain, Belgium, Croatia, Brazil, Austria, Italy, Costa Rica, Germany, Israel, Thailand, Turkey, Russian Federation, United Kingdom, Taiwan, Philippines, India, Chile, Finland, Greece, Sl... and more
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
First People's Hospital of Hangzhou

Recruiting

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Relapsed Small Cell Lung Cancer | Anlotinib

China
Mansoura University

Recruiting

The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence

Death | Wilms Tumor | Relapse

Egypt
Nordic Society of Gynaecological Oncology - Clinical...
Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Recruiting

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (DOVACC)

Ovarian Cancer

Denmark
Peter MacCallum Cancer Centre, Australia

Recruiting

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA)

Metastatic Triple Negative Breast Cancer

Australia
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC; OSE Immunotherapeutics

Recruiting

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA)

Relapsed Ovarian Cancer | Platinum-sensitive Ovarian Cancer

Belgium, France, Germany
Shanghai Pulmonary Hospital, Shanghai, China
Chinese Academy of Sciences

Recruiting

Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

Small Cell Lung Cancer

China
Hoag Memorial Hospital Presbyterian

Recruiting

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Prostate Cancer

United States
Fudan University
M.D. Anderson Cancer Center; Henan Cancer Hospital; Jiangsu Cancer Institute... and other collaborators

Recruiting

Genomic Study of Relapse Esophageal Cancer After Radiotherapy

Esophageal Cancer | Radiation Exposure | Gene Mutation-Related Cancer

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)

Hematological Malignancies

United States, Belgium, Korea, Republic of, China, Germany, Israel, Netherlands, Japan, Spain, France, Poland
Eureka Therapeutics Inc.

Recruiting

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2)

Liver Neoplasms | Hepatocellular Carcinoma (HCC) | Liver Cancer | Hepatoblastoma | Metastatic Liver Cancer | HEMNOS

United States
Swiss Group for Clinical Cancer Research

Recruiting

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Bladder Cancer

Switzerland
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Celgene

Recruiting

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Lymphoma Nonhodgkin

Japan
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell Carcinoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

CD7+ Acute Leukemia | CD7+ Lymphoma

China
Sellas Life Sciences Group
Sellas Life Sciences Group

Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

Hematologic Malignancies

United States, China
Tongji Hospital
Nanjing IASO Biotechnology Co., Ltd.

Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (CARTinNS)

Multiple Sclerosis | Autoimmune Diseases of the Nervous System | Autoimmune Diseases | Myasthenia Gravis | Neuromyelitis Optica Spectrum Disorder | Autoimmune Encephalitis | Idiopathic Inflammatory Myopathies | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Myelin Oligodendrocyte Glycoprotein... and other conditions

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
KAEDI

Not yet recruiting

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Glioma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor

China
Institut Cancerologie de l'Ouest

Recruiting

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin (REPAIR)

Prostate Cancer

France
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma of Soft Tissue

China
Xing Xie

Recruiting

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Efficacy and Safety

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Harpoon Therapeutics

Recruiting

Study in Patients With Advanced Cancers Associated With Expression of DLL3

Neuroendocrine Carcinoma | Small-Cell Lung Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Seagen Inc.

Recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States, Canada, Puerto Rico
Tayu Huaxia Biotech Medical Group Co., Ltd.

Recruiting

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Locally Advanced /Metastatic Solid Tumors | Relapsed or Refractory Lymphomas

China
Centre Jean Perrin

Recruiting

Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients (INSTIGO)

Triple Negative Breast Cancer

France
Institut Curie

Recruiting

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) (SALOME)

Uveal Melanoma

France
AffyImmune Therapeutics, Inc.

Recruiting

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Anaplastic Thyroid Cancer | Relapsed/Refractory Poorly Differentiated Thyroid Cancer

United States
Daiichi Sankyo Co., Ltd.

Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Solid Tumor | Metastatic Solid Tumor | Advanced Cancer

Japan, United States, Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Relapsed/Refractory Hematological Malignancies

China
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditions

United States
Medical University Innsbruck

Recruiting

Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria

Recurrent Ovarian Carcinoma

Austria
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Solid Tumor | Liver Cancer

China
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Dana-Farber Cancer Institute; National Institutes...

Recruiting

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Ovarian Cancer

United States

Search clinical trials for: local relapse

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations